ACLX
MaterialsArcellx Inc
$115.07+0.03 (+0.03%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving ACLX Today?
No stock-specific AI insight has been generated for ACLX yet. Check back soon — insights are generated from recent news analysis.
Fundamentals
Market Cap$6.7B
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume—
Avg Volume (10D)—
Shares Outstanding58.5M
ACLX News
22 articles- Gilead Sciences Q1 Earnings Call HighlightsMarketbeat·May 8, 2026
- Here’s Why Roivant Sciences Ltd (ROIV) Rallied in Q1Yahoo Finance·May 4, 2026
- Gilead’s HIV Priority Review And Arcellx Deal Refocus Long‑Term StoryYahoo Finance·May 2, 2026
- Gilead Sciences Annual Meeting: Directors, Pay Win Big; Pipeline Launches and Acquisitions HighlightedMarketbeat·Apr 30, 2026
- Gilead Sciences Completes Acquisition of Arcellx Ahead of Potential Commercial Launch of Anito-celYahoo Finance·Apr 28, 2026
- Are Medical Stocks Lagging Arcellx (ACLX) This Year?Yahoo Finance·Apr 27, 2026
- Gilead Sciences (GILD) Set to Acquire ArcellxYahoo Finance·Apr 27, 2026
- Gilead Deepens Oncology Reach And HIV Prevention With Arcellx And LenacapavirYahoo Finance·Apr 19, 2026
- Gilead Receives All Required Regulatory Approvals for the Acquisition of Arcellx and Extends Tender OfferYahoo Finance·Apr 17, 2026
- Gilead’s Tubulis Deal Recasts Oncology Ambitions And HIV Reliance RisksYahoo Finance·Apr 11, 2026
- Gilead Sciences' Tubulis Buy Underscores Shift Beyond HIV, Oppenheimer SaysYahoo Finance·Apr 8, 2026
- Assessing Arcellx (ACLX) Valuation After Strong Multi‑Year Share Price GainsYahoo Finance·Apr 8, 2026
- Gilead Sciences Details Tubulis, Ouro, Arcellx Deals as Pipeline Catalyst, 2026 Updates LoomMarketbeat·Apr 7, 2026
- Gilead Sciences Is Betting on a Bavarian Biotech For Its ComebackMoby·Apr 7, 2026
- Gilead Acquisition Spree Continues With $3 Billion Tubulis DealBenzinga·Apr 7, 2026
- Gilead Sciences to Acquire Cancer Treatment Developer Tubulis For Up To $5 BillionYahoo Finance·Apr 7, 2026
- Gilead continues M&A surge with $3.1B deal for ADC specialist TubulisBiopharmadive·Apr 7, 2026
- Gilead Extends Tender Offer to Acquire ArcellxYahoo Finance·Apr 1, 2026
- Can Gilead's Recent Acquisitions Strengthen Its Long-Term Growth Outlook?Yahoo Finance·Mar 27, 2026
- Gilead doubles down on cell therapy: Inside the $7.8bn Arcellx acquisitionPharmaceutical-technology·Mar 25, 2026
- Gilead Eyes $2.2 Billion Autoimmune Push With Ouro DealYahoo Finance·Mar 24, 2026
- Gilead Powers Up Its Inflammation Pipeline With Over $1.5 Billion AcquisitionBenzinga·Mar 24, 2026
All 22 articles loaded
Price Data
Open$0.00
Previous Close$115.07
Day High$0.00
Day Low$0.00
52 Week High—
52 Week Low—
Fundamentals
Market Cap$6.7B
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume—
Avg Volume (10D)—
Shares Outstanding58.5M
About Arcellx Inc
Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.
MaterialsBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Company Details
Security TypeStock
ExchangeNASDAQ
Currency—
Round Lot—
SICBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
CIK—
Composite FIGI—
Share Class FIGI—